Guardion Health Sciences Stock Needs to Give Investors More Than Survival

Friday, February 26, 2021 | Chris Markoch
Guardion Health Sciences Stock Needs to Give Investors More Than Survival

Let me start by saying that Guardion Health Sciences (NASDAQ:GSHI) is one of the riskiest penny stocks you can buy. The company is a biotech/neutraceutical company that has been trading below $1 for the better part of 18 months.

The company is facing a delisting threat but was given a deadline of March 15 to come into compliance. However, it appears that the stock has the attention of the Reddit crowd. First, in early January, the stock rose sharply on significantly higher trading volume.

At that time, it failed to capture the $1 mark. However, traders took another run at the stock in mid-February. This time, the effort was successful. However GSHI stock has not been able to hold those gains.

There’s nothing wrong with that. And even if the company fails to fall into compliance, it appears they have an equity distribution agreement in place with Maxim. That would seem to take the most immediate concern of bankruptcy off the table.

That may be enough for some investors. It’s not for me. But let’s take a closer look.

Medical Food and Medical Devices

Guardion Health has two primary businesses. They are a manufacturer and distributor of medical foods for ocular health, particularly in the area of macular degeneration. And they sell medical devices through VectorVision, a wholly owned subsidiary. The company also sells “neutraceutical” food products for consumer health.

The company has a good story when it comes to age-related macular degeneration (AMD). This is the leading cause of vision loss in the United States. It’s a progressive disease that affects 14% of White Americans over the age of 80. According to Guardion, “approximately 11 million Americans have some form of AMD”. And that number is expected to double to nearly 22 million by 2050.

With those statistics in mind, finding ways to slow the progression could enhance the quality of life for millions of Americans. And the company’s flagship product, Lumega-Z, contains all three macular carotenoids (lutein, zeaxanthin and meso-zeaxanthin) and other antioxidant and anti-inflammatory ingredients that are considered essential to maintaining retinal health.

The composition of Lumenga-Z contains vision-specific nutritional ingredients because the human body cannot naturally produce carotenoids.

Not a Clear Business Plan

I’m not going to disparage the company’s neutraceutical food sector. Alternative health is controversial, but has its true believers. Chances are, if you have a condition, there’s a “natural” remedy that will make claims to treat it. While many doctors won’t endorse them, they probably will not steer you from them if they help.

The first concern I have is that it doesn’t seem to fit with their other business unit. Medical foods of the kind they offer for treatment of AMD are different from neutraceuticals. So, on paper, it appears that they’re hoping to generate revenue from this business unit to help fund the others.

And that leads to my second problem. The company does not appear to be generating much revenue. In Guardion’s last earnings report, which they delivered $0.25 million in sales. That was down significantly from the $1.19 million they had posted in the previous quarter.

GHSI Stock Is a Risk Without Much Reward

I don’t root for any stock to go bankrupt. And I don’t believe that fate will befall Guardion Health Sciences at this time. But that doesn’t make it a sound investment.

With that in mind, the company is scheduled to report earnings sometime in late March. At that time, there should be much more clarity about the company meeting compliance. And investors will get another look at revenue.


Featured Article: What is a balanced fund?

7 Stocks That Cathie Wood is Buying And You Should Too

If you’re an investor that likes to go with the “hot hand,” then they don’t get much hotter than Cathie Wood. The founder and CEO of ARK Investment Management delivered returns of over 100% in all five of her firm’s exchange-traded funds (ETFs) in 2020.

The names of her funds showcase some of the hottest emerging growth trends in the market: financial technology (fintech), genomic revolution, innovation, autonomous technology/robotics, and next generation internet.

As you would expect, these funds contain some of the hottest growth stocks from the past year. And in the aftermath of the tech selloff, Wood is not backing away. In fact, she’s doubling down on her strategy. It might not be exactly a matter of being greedy while others are fearful; perhaps more like being prepared while others are distracted.

But the other thing about Wood’s selections is that many of them are not obscure names. These are companies that were among the hottest names in 2020. Wood simply believes that they still have room to run. And that’s one reason you should consider making them a part of your portfolio.

In this special presentation, we’re giving you just seven of the stocks that Cathie Wood is buying or has bought recently. We’ve attempted to pick out at least one stock from each of the ARK ETFs. As with any investment decision, it’s important that you perform your own research before making a decision.

View the "7 Stocks That Cathie Wood is Buying And You Should Too".

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.